Camlipixant

Summary

Camlipixant (CHEMBL5095035) is a phase-3 clinical-stage small molecule targeting P2RX3; indicated across 2 conditions.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (P2RX3)
• Indications: 2 conditions
• Clinical trials: 12
• Chemistry: 458.5 Da · C23H24F2N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095035
Name	Camlipixant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	76955630
Molecular formula	C23H24F2N4O4
Molecular weight	458.5
InChIKey	SEHLMRJSQFAPCJ-HNNXBMFYSA-N

SMILES: CC1=CC2=NC(=C(N2C=C1)C[C@H]3CN(CCO3)C(=O)OC)C4=C(C=C(C=C4F)C(=O)NC)F

IUPAC name: methyl (2S)-2-[[2-[2,6-difluoro-4-(methylcarbamoyl)phenyl]-7-methylimidazo[1,2-a]pyridin-3-yl]methyl]morpholine-4-carboxylate

Also known as: AZ-13410937, AZ13410937, Blu-5937, BLU-5937, BLU5937, Camlipixant, NEO-5937, NEO5937, CAMLIPIXANT

Patent coverage: 52 distinct patent families (161 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
P2RX3	P2X3	Antagonist	7.6	1.6%	P56373

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): P2RX3.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Elevation of cytosolic Ca2+ levels	1	P2RX3
Platelet homeostasis	1	P2RX3

Dominant GO biological processes

GO term	Targets
response to hypoxia	1
signal transduction	1
neuromuscular synaptic transmission	1
response to heat	1
response to cold	1
response to mechanical stimulus	1
response to carbohydrate	1
positive regulation of calcium ion transport into cytosol	1
urinary bladder smooth muscle contraction	1
peristalsis	1
regulation of synaptic plasticity	1
behavioral response to pain	1
positive regulation of calcium-mediated signaling	1
sensory perception of taste	1
establishment of localization in cell	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4).

The 2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE1	6
PHASE2	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05599191	PHASE3	ACTIVE_NOT_RECRUITING	A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777	PHASE3	ACTIVE_NOT_RECRUITING	A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT07519395	PHASE2	NOT_YET_RECRUITING	A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT03979638	PHASE2	TERMINATED	A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
NCT04678206	PHASE2	COMPLETED	Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT04693195	PHASE2	COMPLETED	A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
NCT03638180	PHASE1	COMPLETED	BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
NCT05899829	PHASE1	COMPLETED	Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
NCT05959447	PHASE1	COMPLETED	Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
NCT06179537	PHASE1	COMPLETED	Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
NCT06222892	PHASE1	COMPLETED	A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
NCT06497517	PHASE1	COMPLETED	A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

6 molecules share ≥1 primary target. Top 6 by shared-target count:

Molecule	Source	Status	Shared targets
GEFAPIXANT	ChEMBL	Phase 4 (approved)	P2RX3
PROGESTERONE	ChEMBL	Phase 4 (approved)	P2RX3
SURAMIN	ChEMBL	Phase 3	P2RX3
ADENOSINE TRIPHOSPHATE	ChEMBL	Phase 2	P2RX3
ELIAPIXANT	ChEMBL	Phase 2	P2RX3
theophylline	PubChem	Approved	P2RX3